This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Partnering, Business Development & Licensing
search
Biotech Showcase Interviews

Arena CEO Amit Munshi outlines post-Belviq ambitions for Ralinepag and Etrasimod

Posted by on 05 February 2018
Share this article

Having joined Arena in 2016 to turn the company around, CEO Amit Munshi negotiated the handing over of rights to the weight loss product, lorcaserin, to partner Eisai, and set about refocusing the business on its lead programs ralinepag and etrasimod. Cutting out costs of USD 100 million and raising USD 270 million from institutional investors, Arena saw its valuation rise from about USD 350 million to some USD 1.6 billion in 2017. Munshi reveals to Scrip his plans for his lead programs.

Share this article

Sign up for Partnering, Business Development & Licensing email updates

keyboard_arrow_down